Latest:
Dr. Cheng on the Role of T-DM1 in HER2+ Breast Cancer
Yee Chung Cheng, MD, associate professor of medicine, Medical College of Wisconsin, discusses the role of T-DM1 in patients with HER2-positive breast cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Yelena Novik, MD
Latest:
Dr Novik on Emergent Treatment Options in ER+ Breast Cancer
Yelena Novik, MD, discusses advancements and emerging trends that have been seen in the treatment of patients with advanced estrogen-receptor–positive breast cancer, citing clinical trials that have helped push the treatment armamentarium forward.
Yelena Y. Janjigian, MD
Yelena Y. Janjigian, MD, is chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center.
Latest:
Ongoing Research to Watch in Advanced Gastric/GEJ Cancer
Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss ongoing trials that could help refine the gastric/GEJ cancer treatment paradigm.
Yin Zhang, PhD
Latest:
Radiotherapy in the Modern Era in the Management of Langerhans Cell Histiocytosis
Intensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.
Yixing Jiang, BM, PhD
Latest:
Dr. Jiang on the Future of Immunotherapy in Microsatellite Stable Colorectal Cancer
Yixing Jiang, BM, PhD, associate professor of medicine, director, Gastrointestinal Medical Oncology Marlene Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, discusses the future of immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).
Yogen Saunthararajah, MD
Latest:
Novel AML Strategies Aim to Restore Regulatory Gene Functions
Acute promyelocytic leukemia, a rare genetic subtype of de novo acute myeloid leukemia is treated not with conventional cytotoxic chemotherapy but with just 2 drugs: all-trans retinoic acid and arsenic trioxide. Given this, an enduring question has been whether noncytotoxic differentiation-restoring therapy can be extended to the most common genetic subtypes of AML.
Yogenthiran Saunthararajah, MD
Latest:
Dr. Saunthararajah on Mechanisms of Resistance to 5-Azacytidine /Decitabine in MDS-AML
Yogenthiran Saunthararajah, MD, Department of Hematologic Oncology and Blood Disorders at Cleveland Clinic, professor of Medicine, co-leader, Developmental Therapeutics Program of the Case Comprehensive Cancer Center, discusses mechanisms of resistance to 5-azacytidine and decitabine in patients with myelodysplastic syndromes-acute myeloid leukemia.
Yong-Chen William Lu, PhD
Latest:
Yong-Chen William Lu on Adoptive T-Cell Therapy in Solid Tumors
Yong-Chen William Lu, PhD, a fellow in the Surgery Branch of the National Cancer Institute, discusses a CD4 T-cell immunotherapy targeting MAGE-A3 that is showing early clinical responses in patients with metastatic cancer.
You-cai Zhu, MD, PhD
Latest:
Dr. Zhu on Primary Resistance to Osimertinib in EGFR-Mutant NSCLC
You-cai Zhu, MD, PhD, Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, discusses primary resistance to osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).
Yung-Jue Bang, MD, PhD
Latest:
Dr. Bang on Pembrolizumab for Advanced Gastric Cancer
Yung-Jue Bang, MD, PhD, discusses pembrolizumab for the treatment of advanced gastric cancer. Pembrolizumab was investigated as part of the KEYNOTE-012 study, which looked at the checkpoint inhibitor across several solid tumors.
Yuqin Song, MD, PhD
Latest:
Dr. Song on Zanubrutinib Activity in Relapsed/Refractory MCL
Yuqin Song, MD, PhD, chief physician and deputy director of the Lymphoma Department at Peking University Cancer Hospital, Beijing, China, discusses the updated data from the phase II trial evaluating the efficacy of zanubrutinib (BGB-3111-206) in patients with relapsed/refractory mantle cell lymphoma.